UNION therapeutics A/S (UNION), a privately-held pharmaceutical development company, announced on Thursday that it has enrolled its first patient in ADESOS, a Phase 2b dose-finding study assessing the safety and efficacy of orismilast MR tablet in adults with moderate to severe atopic dermatitis (AD).
The aim of the study is to find the appropriate dosages for Phase three studies.
The Phase 2b study is a randomised, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of orismilast MR tablets. It is enrolling around 210 patients who will be randomised to three active doses (20mg, 30mg, and 40 mg) of orismilast compared to placebo administered twice daily. The study will be carried out at centres in Europe and the US.
Merck's sotatercept gains priority review for PAH treatment
Antibe gains approval for otenaproxesul PK/PD study
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Everads Therapy signs license, collaboration and supply agreement with Kriya Therapeutics
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial
Armata Pharmaceuticals doses first patient in Phase 2a of AP-SA02 diSArm study
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
EXACT Therapeutics' ACTIVATE trial shows promise in enhancing chemotherapy efficacy
Sanofi granted Priority Review for EoE treatment in young children
Pierre Fabre Laboratories signs long-term collaboration with Vernalis (R&D)
BioArctic and Eisai secure approval for LEQEMBI infusion in Japan for Alzheimer's disease treatment